SQZ Biotech and AskBio collaborate to overcome AAV immunogenicity
Patients’ immune systems generating neutralising antibodies toward therapeutic AAVs is one of gene therapy’s biggest challenges and SQZ's proprietary technology proposes tolerising antigen carriers